title: [Malignant head and neck melanoma: Part 2: Therapy].
abstract: Resection margins of melanomas in the head and neck region often have to be adapted according anatomical circumstances. In the case of thicker primary tumors or after complete resection of locoregional lymph node metastases, adjuvant therapy with interferon-α can be performed; in some cases, adjuvant radiotherapy may also be indicated. In the case of inoperable lymph node or distant metastases, systemic treatment is required. Beside well-established mono- or polychemotherapy regimens, newer targeted therapies with BRAF inhibitors (vemurafenib, dabrafenib), mitogenic-activated protein kinase (MEK) inhibitors (trametinib, binimetinib, and cobimetinib), and kinase inhibitors (imatinib, sunitinib, nilotinib, dasatinib) are also available.
authors.affiliation: Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum des Saarlandes, Kirrbergerstrasse, 66421, Homburg/Saar, Deutschland, claudia.pfoehler@uks.eu.
authors.forename: C
authors.initials: C
authors.lastname: Pföhler
authors.forename: T
authors.initials: T
authors.lastname: Vogt
authors.forename: C S L
authors.initials: CS
authors.lastname: Müller
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D059248:Chemoradiotherapy / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D008545:Melanoma / Q000175:diagnosis / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy*